Efficacy and imaging evaluation of 177Lu-labeled antibody-drug conjugates as a potential theranostic agent for HER2-positive breast cancer

被引：0
|
作者：
Kim, Heejung [1 ]
Shin, Eunbi [1 ]
Lee, JooHyun [1 ]
Yoo, Ran Ji [1 ]
Park, Jang Woo [1 ]
Chung, Hye Kyung [1 ]
Shim, Jae-Hoon [1 ]
机构：
[1] Korea Inst Radiol & Med Sci KIRAMS, Seoul, South Korea
来源：
NUCLEAR MEDICINE AND BIOLOGY | 2021年 / 96-97卷
关键词：
D O I：
暂无
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
SP-124
引用
收藏
页码：S104 / S105
页数：2
相关论文
共 50 条
  • [41] Impacts of genomic alterations on the efficacy of HER2-targeted antibody-drug conjugates in patients with metastatic breast cancer
    Huang, Riqing
    Hu, Anqi
    Rong, Qixiang
    Shu, Ditian
    Chen, Meiting
    Yang, Wei
    Zhang, Yue
    Zheng, Qiufan
    An, Xin
    Xue, Cong
    Li, Haifeng
    Shi, Yanxia
    JOURNAL OF TRANSLATIONAL MEDICINE, 2025, 23 (01)
  • [42] Theranostic application of 64Cu/177Lu-labeled anti-Trop2 monoclonal antibody in pancreatic cancer tumor models
    Cuicui Li
    Jun Liu
    Xu Yang
    Qi Yang
    Wenpeng Huang
    Mingyu Zhang
    Dandan Zhou
    Rong Wang
    Jianhua Gong
    Qingfang Miao
    Lei Kang
    Jigang Yang
    European Journal of Nuclear Medicine and Molecular Imaging, 2022, 50 : 168 - 183
  • [43] Reversible versus irreversible tyrosine kinase inhibitors (TKIs) combined with antibody-drug conjugates (ADCs) in HER2-positive (HER2+) breast cancer (BC) cell lines
    Ashfield, Niall
    Mahdi, Amira F.
    Conlon, Neil T.
    Crown, John
    Collins, Denis M.
    CANCER RESEARCH, 2023, 83 (05)
  • [44] Mechanisms of action and resistance to anti-HER2 antibody-drug conjugates in breast cancer
    Saleh, Khalil
    Khoury, Rita
    Khalife, Nadine
    Chahine, Claude
    Ibrahim, Rebecca
    Tikriti, Zamzam
    Le Cesne, Axel
    CANCER DRUG RESISTANCE, 2024, 7 : 2 - 15
  • [45] Comparative Efficacy of Tyrosine Kinase Inhibitors and Antibody-Drug Conjugates in HER2-Positive Metastatic Breast Cancer Patients with Brain Metastases: A Systematic Review and Network Meta-Analysis
    Wang, Yan
    Xu, Hangcheng
    Han, Yiqun
    Wu, Yun
    Wang, Jiayu
    CANCERS, 2022, 14 (14)
  • [46] Current and Emerging Role of Antibody-Drug Conjugates in HER2-Negative Breast Cancer
    Abelman, Rachel Occhiogrosso
    Keenan, Jennifer C.
    Ryan, Phoebe K.
    Spring, Laura M.
    Bardia, Aditya
    HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 2023, 37 (01) : 151 - 167
  • [47] Local Radiation Treatment of HER2-Positive Breast Cancer Using Trastuzumab-Modified Gold Nanoparticles Labeled with 177Lu
    Cai, Zhongli
    Yook, Simmyung
    Lu, Yijie
    Bergstrom, Dane
    Winnik, Mitchell A.
    Pignol, Jean-Philippe
    Reilly, Raymond M.
    PHARMACEUTICAL RESEARCH, 2017, 34 (03) : 579 - 590
  • [48] Local Radiation Treatment of HER2-Positive Breast Cancer Using Trastuzumab-Modified Gold Nanoparticles Labeled with 177Lu
    Zhongli Cai
    Simmyung Yook
    Yijie Lu
    Dane Bergstrom
    Mitchell A. Winnik
    Jean-Philippe Pignol
    Raymond M. Reilly
    Pharmaceutical Research, 2017, 34 : 579 - 590
  • [49] Next-Generation HER2-Targeted Antibody-Drug Conjugates in Breast Cancer
    Zimmerman, Brittney S.
    Esteva, Francisco J.
    CANCERS, 2024, 16 (04)
  • [50] Antibody-drug conjugates in breast cancer: Marching from HER2-overexpression into HER2-low
    Fan, Pinchao
    Xu, Kun
    BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER, 2023, 1878 (01):
12345